| Species |
Human |
| Protein Construction |
IL-7 R alpha/CD127 (Glu21-Gly236)
Accession # P16871-1 |
hFc |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Human IL7 at 2μg/ml (100μl/Well) on the plate can bind IL-7R alpha/CD127 hFc Chimera, Human. Test result was comparable to standard batch |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
51.6 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 65-75 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Interleukin 7 (IL-7) and its receptor (IL-7R, a heterodimer of IL-7Rα and γc) are essential for normal lymphoid development. IL-7 and IL-7R activate three main pathways: STAT5, PI3K/Akt/mTOR and MEK/Erk, ultimately leading to the promotion of leukemia cell viability, cell cycle progression and growth. |
| Synonyms |
IL-7R alpha; IL7Ra; CD127; CDW127; IL7Rα |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
